Phase 1/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AML.
Blood Adv
; 7(17): 4950-4961, 2023 09 12.
Article
in En
| MEDLINE
| ID: mdl-37339483
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Leukemia, Myeloid, Acute
/
Mitoxantrone
Type of study:
Diagnostic_studies
Limits:
Adult
/
Humans
/
Middle aged
Language:
En
Journal:
Blood Adv
Year:
2023
Document type:
Article
Country of publication:
United States